Britain's Most Admired No. 5: GlaxoSmithKline, Andrew Witty

Witty took over as GSK's boss two years ago, and has been busy reshaping the pharma giant to take better advantage of emerging markets. To that end, he is shifting focus away from traditional high-margin blockbuster drugs to a lower-margin but more diverse and less risky product portfolio. He has also relaxed the firm's notoriously rigid pricing policy to bring much-needed medicines within the budgets of the developing world. The shift seems to be working - Q3 sales are up 15% to £6.8bn.

Last Updated: 09 Oct 2013


Find this article useful?

Get more great articles like this in your inbox every lunchtime

Why your turnaround is failing

Be careful where you look for advice.

Crash course: How to find hidden talent

The best person for the role might be closer than you think.

What they don't tell you about flexible working

The realities of ditching the nine to five don't always live up to the hype....

The business case for compassion: Nando's, Cisco and Innocent Drinks

Consciously, systematically humane cultures reap enormous benefits, argues academic Amy Bradley.

“I have great respect for the capital markets, but I don’t want their ...

Exclusive: PA Consulting CEO Alan Middleton on acquisition bids, growth strategy and life after private...

Dame Inga Beale: “I was told I didn’t deserve to be alive”

The former CEO of Lloyd's of London reveals the leadership lessons that shaped her career...